İnsomnia (Uykusuzluk)
Özet
İnsomnia, uykuya başlama veya uykuyu sürdürme güçlüğü ile karakterize, yaşam kalitesini ve gündüz işlevselliğini ciddi şekilde bozan yaygın bir sağlık sorunudur. Kadınlarda ve ileri yaştaki bireylerde daha sık görülen bu bozukluk, depresyon ve anksiyete gibi psikiyatrik durumlar için önemli bir risk faktörü oluştururken, fiziksel komorbiditelerle de iki yönlü bir ilişki içindedir. Tanı sürecinde klinik öykü ve uyku günlüğü temel araçlar olarak kullanılırken, 3P modeli gibi davranışsal yaklaşımlar uykusuzluğun akut durumdan kronikleşmeye geçişini açıklamaya yardımcı olmaktadır. Tedavi yaklaşımı, uyku hijyeni, uyaran kontrolü ve uyku kısıtlama gibi non-farmakolojik yöntemlerin yanı sıra hastanın ihtiyacına göre düzenlenen çeşitli sınıflardaki ilaç tedavilerini içermektedir.
Insomnia is a prevalent health issue characterized by difficulty initiating or maintaining sleep, which significantly impairs quality of life and daytime functioning. This disorder, more common in women and older adults, serves as a major risk factor for psychiatric conditions like depression and anxiety while maintaining a bidirectional relationship with various physical comorbidities. Clinical history and sleep diaries are essential diagnostic tools, with the 3P model helping to explain the transition from acute to chronic insomnia. The treatment approach encompasses non-pharmacological methods such as sleep hygiene, stimulus control, and sleep restriction, alongside tailored pharmacological interventions based on individual patient needs.
Referanslar
Riemann D, Spiegelhalder K, Feige B, et al. The hyperarousal model of insomnia: a review of the concept and its evidence. Sleep Med Rev. 2010;14:19-31.
Riemann D, Nissen C, Palagini L, Otte A, Perlis ML, Spiegelhalder K. The neurobiology, investigation, and treatment of chronic insomnia. Lancet Neurol. 2015;14:547-558.
Espie CA, Broomfield NM, MacMahon KMA, Macphee LM, Taylor LM. The attention-intention-effort pathway in the development of psychophysiologic insomnia: a theoretical review. Sleep Med Rev. 2006;10:215-245.
Harvey AG. Identifying safety behaviors in insomnia. J Nerv Ment Dis. 2002;190:16-21.
Baglioni C, Nanovska S, Regen W, Spiegelhalder K, Feige B, Nissen C, et al. Sleep and mental disorders: a meta-analysis of polysomnographic research. Psychol Bull. 2016;142:969-990.
Baglioni C, Battagliese G, Feige B, Spiegelhalder K, Nissen C, Voderholzer U, et al. Insomnia as a predictor of depression: a meta-analytic evaluation of longitudinal epidemiological studies. J Affect Disord. 2011;135:10-19.
Li L, Wu C, Gan Y, Qu X, Lu Z. Insomnia and the risk of depression: a metaanalysis of prospective cohort studies. BMC Psychiatr. 2016;16:375.
Pigeon WR, Bishop TM, Krueger KM. Insomnia as a precipitating factor in new onset mental illness: a systematic review of recent findings. Curr Psychiatr Rep. 2017;19:44.
Qaseem A, Kansagara D, Forciea MA, et al. Clinical guidelines committee of the American college of physicians. Management of chronic insomnia disorder in adults: a clinical practice guideline from the American college of physicians. Ann Intern Med. 2016;165:125-133.
Riemann D, Baum E, Cohrs S, et al. S3- € Leitlinie nicht erholsamer schlaf/schlafstorungen. Somnologie. 2017;21:2-44.
Riemann D, Baglioni C, Bassetti C, et al. European guideline for the diagnosis and treatment of insomnia. J Sleep Res. 2017;26:675-700.
Trauer JM, Qian MY, Doyle JS, Rajaratnam SMW, Cunnington D. Cognitive behavioral therapy for chronic insomnia: a systematic review and metaanalysis. Ann Intern Med. 2015;163:191-204.
American Psychiatric Association. Diagnostic and statistical manual of mental disorders, 5th ed. Arlington: American Psychiatric Association, 2013.
American Academy of Sleep Medicine. International classification of sleep disorders, 3rd ed. Darien: American Academy of Sleep Medicine, 2014.
Johnson EO. Epidemiology of insomnia: from adolescence to old age. Sleep Med Clin. 2006;1:305-317.
Mellinger GD, Balter MB, Uhlenhuth EH. Insomnia and its treatment. Prevalence and correlates. Arch Gen Psychiatry. 1985;42:225-232.
Benbir G, Demir AU, Aksu M, et al. Prevalence of insomnia and its clinical correlates in a general population in Turkey. Psychiatry and clinical neurosciences. 2015; 69(9), 543-552.
Roth T. Insomnia: definition, prevalence, etiology, and consequences. J Clin Sleep Med. 2007;3(5):7-10.
Morin CM, Bélanger L, LeBlanc M, et al. The natural history of insomnia: a population-based 3-year longitudinal study. Arch Intern Med. 2009;169:447-53.
Ohayon, M. M. Epidemiology of insomnia: what we know and what we still need to learn. Sleep medicine reviews. 2002;6(2):97-111.
Beaulieu-Bonneau S, LeBlanc M, Mérette C, et al. Family history of insom-nia in a population-based sample. Sleep. 2007;30:1739-1745.
Kim K, Uchiyama M, Okawa M, et al. An epidemiological study of insom-nia among the Japanese general population. Sleep. 2000;23:41-47.
Ohayon M. Epidemiological study on insomnia in the general population. Sleep. 1996;19(3):7-15.
Leger D, Guilleminault C, Dreyfus JP, et al. Prevalence of insomnia in a survey of 12,778 adults in France. J Sleep Res. 2000;9:35-42.
Bixler EO, Kales A, Soldatos CR, et al. Prevalence of sleep disorders in the Los Angeles metropolitan area. Am J Psychiatry. 1979;136:1257-1262.
Maggi S, Langlois JA, Minicuci N, et al. Sleep complaints in community-dwelling older persons: prevalence, associated factors, and reported caus-es. J Am Geriatr Soc. 1998;46:161-168.
Foley DJ, Monjan AA, Brown SL et al. Sleep complaints among elderly per-sons: an epidemiologic study of three communities. Sleep. 1995;18:425-432.
Weissman MM, Bland RC, Canino GJ, et al. Cross-national epidemiology of major depression and bipolar disorder. JAMA. 1996;276:293-299.
Ford DE, Kamerow DB. Epidemiologic study of sleep disturbances and psychiatric disorders. An opportunity for prevention? JAMA. 1989;262:1479-1484.
Henderson S, Jorm AF, Scott LR, et al. Insomnia in the elderly: its preva-lence and correlates in the general population. Med J Aust. 1995;162:22-24.
Tamura H, Nishida T, Tsuji A, et al. Association between excessive use of mobile phone and insomnia and depression among Japanese adoles-cents. Int J Environ Res Publ Health. 2017;14:701.
Ohayon M, Guilleminault C. Epidemiology of sleep disorders. Lee-Chiong, Teofilo (Eds): In: Sleep: a comprehensive handbook. New Jersey, John Wiley and Sons; 2006 73-82 Wiley, 2005. p. 73-82.
Gislason T, Almqvist M. Somatic diseases and sleep complaints. An epi-demiological study of 3,201 Swedish men. Acta Med Scand. 1987;221:475-481.
Stoschitzky K, Sakotnik A, Lercher P, et al. Influence of beta-blockers on melatonin release. Eur J Clin Pharmacol. 1999;55:111-115.
Matteson-Rusby SE, Pigeon WR, Gehrman P, et al. Why treat insomnia? Prim Care Companion J Clin Psychiatry. 2010;12:27019.
American Psychiatric Association. Diagnostic and statistical manual of mental disorders, 5th ed. Arlington: American Psychiatric Association, 2013.
American Academy of Sleep Medicine. International classification of sleep disorders, 3rd ed. Darien: American Academy of Sleep Medicine, 2014.
Krystal AD, Prather AA, Ashbrook LH. The assessment and management of insomnia: an update. World Psychiatry. 2019;18(3):337-352.
Spielman AJ, Caruso LS, Glovinsky PB. A behavioral-perspective on in-somnia treatment. Psychiatr Clin North Am. 1987;10:541-553.
Brainard GC, Hanifin JP, Greeson JM, et al. Action spectrum for melatonin regulation in humans: evidence for a novel circadian photoreceptor. J Neurosci. 2001;21:6405-6412.
Yang C-M, Spielman AJ, Glovinsky P. Nonpharmacologic strategies in the management of insomnia. Psychiatr Clin North Am. 2006;29:895-919.
Ebben MR, Spielman AJ. Non-pharmacological treatments for insomnia. J Behav Med. 2009;32:244-254.
Schutte-Rodin S, Broch L, Buysse D et al. Clinical guideline for the evalu-ation and management of chronic insomnia in adults. J Clin Sleep Med. 2008;4:487-504.
Sevim, S (2011) Sirkadyen Ritim Bozuklukları. Uyku Fizyolojisi ve Hastalıkları. H Kaynak, S Ardıç (Eds), 325-332. İstanbul, Nobel Matbaacılık.
Krystal AD, Edinger JD, Wohlgemuth WK, et al. NREM sleep EEG frequen-cy spectral correlates of sleep complaints in primary insomnia subtypes. Sleep. 2002;25:630-640.
Johns MW. A new method for measuring daytime sleepiness: the Ep-worth Sleepiness Scale. Sleep. 1991;14:540-545.
Morin CM, Belleville G, Bélanger L, et al. The Insomnia Severity Index: psychometric indicators to detect insomnia cases and evaluate treatment response. Sleep. 2011;34:601-608.
Morin CM, Vallières A, Ivers H. Dysfunctional beliefs and attitudes about sleep (DBAS): validation of a brief version (DBAS-16). Sleep. 2007;30:1547-1554.
Buysse DJ, Reynolds CF 3rd, Monk TH, et al. The Pittsburgh Sleep Quality Index: a new instrument for psychiatric practice and research. Psychiatr Res. 1989;28:193-213.
Bootzin RR. Stimulus control treatment for insomnia. Proceedings of the American Psychological Association. 1972;7:395-396.
Spielman AJ, Caruso LS, Glovinsky PB. A behavioral perspective on insomnia treatment. Psychiatric Clinics of North America. 1987;10(4),541-553.
Katzung BG, Masters SB, Trevor AJ. (2009) Basic and clinical pharmacology. New York: McGraw-Hill Medical.
Sieghart W, Sperk G. Subunit composition, distribution and function of GABA(A) receptor subtypes. Curr Top Med Chem. 2002;2:795-816.
Krystal AD. A compendium of placebo-controlled trials of the risks/ben-efits of pharmacological treatments for insomnia: the empirical basis for U.S. clinical practice. Sleep Med Rev. 2009;13:265-274.
Ng KY, Leong MK, Liang H, et al. Melatonin receptors: distribution in mam-malian brain and their respective putative functions. Brain Struct Funct. 2017;222:2921-2939.
Ferracioli-Oda E, Qawasmi A, Bloch MH. Meta-analysis: melatonin for the treatment of primary sleep disorders. PLoS One. 2013;8(5):e63773.
Buscemi N, Vandermeer B, Hooton N et al. The efficacy and safety of ex-ogenous melatonin for primary sleep disorders. A meta-analysis. J Gen Intern Med. 2005;20:1151-1158.
Lerchl A. Melatonin administration alters semen quality in normal men. J Androl. 2004;25:185-186.
Pang SF, Li L, Ayre EA, et al. Neuroendocrinology of melatonin in repro-duction: recent developments. J Chem Neuroanat. 1998;14:157-166.
Herring WJ, Connor KM, Ivgy-May N, et al. Suvorexant in patients with in-somnia: results from two 3-month randomized controlled clinical trials. Biol Psychiatry. 2016;79:136-148.
Herring WJ, Snyder E, Budd K, et al. Orexin receptor antagonism for treat-ment of insomnia: a randomized clinical trial of suvorexant. Neurology. 2012;79:2265-2274.
Michelson D, Snyder E, Paradis E, et al. Safety and efficacy of suvorexant during 1-year treatment of insomnia with subsequent abrupt treatment discontinuation: a phase 3 randomised, double-blind, placebo-controlled trial. Lancet Neurol. 2014;13:461-471.
